Anti-MYBL1 antibody produced in rabbit
SIGMA/HPA008791 - Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Synonym: Anti-A-Myb antibody produced in rabbit; Anti-Myb-related protein A antibody produced in rabbit
Product Type: Chemical
| antibody form | affinity isolated antibody |
| antibody product type | primary antibodies |
| biological source | rabbit |
| clone | polyclonal |
| conjugate | unconjugated |
| form | buffered aqueous glycerol solution |
| immunogen sequence | EANAVLSSLQTIPEFAETLELIESD |
| product line | Prestige Antibodies® Powered by Atlas Antibodies |
| Quality Level | 100 ![]() |
| shipped in | wet ice |
| species reactivity | human |
| storage temp. | −20°C |
| target post-translational modification | unmodified |
| technique(s) | immunohistochemistry: 1:50- 1:200 |
| UniProt accession no. | P10243 ![]() |
| Application: | Anti-MYBL1 antibody produced in rabbit, a Prestige Antibody, is developed and validated by the Human Protein Atlas (HPA) project ![]() and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige . |
| Application: | These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies® protocols and other useful information. |
| Biochem/physiol Actions: | MYBL1 (v-myb avian myeloblastosis viral oncogene homolog-like 1) is partially duplicated in 28% of diffuse astrocytoma grade II tumors. This gene is characterized by recurrent oncogenic truncating rearrangements in pediatric low-grade gliomas. This gene is thought to be involved in the control of differentiation and proliferation of normal B-cells and Burkitt′s lymphoma cells. It also acts as an interacting partner of CBP (CREB-binding protein) protein, where its charged sequence binds with the CREB (cAMP response element-binding protein)-binding domain of CBP. |
| Disclaimer: | Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals. |
| Features and Benefits: | Prestige Antibodies® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section. Every Prestige Antibody is tested in the following ways: • IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues. • Protein array of 364 human recombinant protein fragments. |
| General description: | MYBL1 (v-myb avian myeloblastosis viral oncogene homolog-like 1) gene is localized to human chromosome 8q13.1, and codes for a transcription factor. It is a member of the oncoprotein family called Myb. Its N-terminal contains DNA-binding repeats, and its C-terminal contains two conserved regions. Its c-Myb transactivation domain contains a putative leucine zipper. |
| Immunogen: | Myb-related protein A recombinant protein epitope signature tag (PrEST) |
| Legal Information: | Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany |
| Other Notes: | Corresponding Antigen APREST71002 |
| Physical form: | Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 1 |
| Storage Temp. | −20°C |
| UNSPSC | 12352203 |

